Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Gemcitabine, Oxaliplatin, Rituximab in patients with Non-Hodgkin Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

This statement is based on a regulatory approval from the Health Service Executive:

Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

Citation

R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6510/506_v4_R-Gem_OX.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-08-13	Health Service Executive	Indication approved for reimbursement.